DexCom, Inc. (NASDAQ:DXCM) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given a consensus rating of “Moderate Buy” by the fifteen analysts that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $140.33.

DXCM has been the subject of several research reports. Royal Bank of Canada initiated coverage on DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective for the company. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. UBS Group increased their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Redburn Atlantic started coverage on DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock. Finally, Raymond James increased their target price on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th.

DexCom Stock Performance

DXCM stock opened at $113.38 on Friday. The business has a 50 day moving average of $123.14 and a 200-day moving average of $125.66. DexCom has a 12-month low of $74.75 and a 12-month high of $142.00. The firm has a market cap of $45.09 billion, a PE ratio of 73.15, a P/E/G ratio of 2.77 and a beta of 1.22. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. As a group, sell-side analysts expect that DexCom will post 1.78 earnings per share for the current year.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 427 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now owns 75,877 shares in the company, valued at $8,729,648.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, EVP Michael Jon Brown sold 629 shares of DexCom stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total transaction of $79,411.25. Following the completion of the sale, the executive vice president now owns 68,212 shares of the company’s stock, valued at $8,611,765. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 427 shares of DexCom stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $49,126.35. Following the sale, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 55,735 shares of company stock worth $7,619,347. Corporate insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

Several hedge funds have recently added to or reduced their stakes in the company. HM Payson & Co. increased its holdings in shares of DexCom by 6.0% in the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after buying an additional 100 shares during the period. American Trust purchased a new position in shares of DexCom in the first quarter worth about $212,000. Maxwell Wealth Strategies Inc. purchased a new position in shares of DexCom in the first quarter worth about $1,363,000. Cetera Advisors LLC increased its holdings in shares of DexCom by 593.4% in the first quarter. Cetera Advisors LLC now owns 40,808 shares of the medical device company’s stock worth $5,660,000 after buying an additional 34,923 shares during the period. Finally, Cetera Investment Advisers increased its holdings in shares of DexCom by 76.4% in the first quarter. Cetera Investment Advisers now owns 106,881 shares of the medical device company’s stock worth $14,824,000 after buying an additional 46,297 shares during the period. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.